thyssenkrupp nucera (NCH2) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
13 May, 2026Strategic vision and business model
Focused on driving sustainable industrial transformation through cutting-edge electrolysis technologies for green hydrogen and chlor-alkali markets.
Operates an asset-light business model with a strong balance sheet to support future growth.
Supports customers in achieving climate neutrality with reliable, innovative solutions at industrial scale.
Over 1,000 employees across 10 global locations, with a diversified project pipeline.
Business segments and technology leadership
Two main segments: Green Hydrogen (gH2) and Chlor-Alkali (CA), both leveraging decades of electrolysis expertise.
gH2 segment uses Alkaline Water Electrolysis (AWE) technology, with ~3.5 GW of projects under execution.
CA segment holds ~50% global market share, with over 600 projects and 10 GW installed capacity.
Continuous innovation in cell design, modularization, and digitalization to enhance efficiency and safety.
Financial performance and outlook
FY 2024/25 sales reached €845mn, with CA contributing 46% and gH2 54%.
EBIT improved to €2mn in FY 2024/25, driven by gH2 margin gains and cost discipline.
Net financial assets increased to €673mn, providing resilience and growth capacity.
Adjusted FY 2025/26 outlook: group sales €450–550mn, EBIT for CA €45–65mn, gH2 EBIT -€125 to -€90mn.
Latest events from thyssenkrupp nucera
- Q2 order intake soared while sales and EBIT fell on one-off green hydrogen costs; outlook steady.NCH2
Q2 202615 May 2026 - Strong financials, strategic innovation, and all agenda items approved amid market challenges.NCH2
AGM 202610 Apr 2026 - Order intake guidance raised to €550–850m, but sales and EBIT guidance lowered for FY 2025/26.NCH2
Status update18 Mar 2026 - Record chlor-alkali sales and improved margins offset green hydrogen softness; outlook cautious.NCH2
Q4 202513 Feb 2026 - Sales and EBIT declined sharply, but full-year guidance and order momentum remain strong.NCH2
Q1 202611 Feb 2026 - Record sales and robust backlog, but AWE outlook clouded by regulatory and market delays.NCH2
Q3 20241 Feb 2026 - Record sales and resilient AWE and CA growth drive strong performance amid market challenges.NCH2
Q4 202411 Jan 2026 - Record Q1 sales and EBIT growth, with strong outlook and robust order backlog.NCH2
Q1 202523 Dec 2025 - Q3 sales fell, but raised guidance and margin gains highlight improved outlook.NCH2
Q3 202523 Nov 2025